Multiple Sclerosis Center, Sheba Medical Center, Israel.
J Neuroimmunol. 2012 Nov 15;252(1-2):83-8. doi: 10.1016/j.jneuroim.2012.07.014. Epub 2012 Aug 24.
Multiple sclerosis (MS) is characterized in most patients by a relapsing-remitting disease course. However, the trigger of relapse and the transformation that switches relapse into remission are not clearly understood. To evaluate the key molecular pathways operating in MS relapse and remission we performed peripheral blood gene-expression profiling in 123 MS patients either in relapse (n=34) or remission (n=89) and in comparison with 41 matched healthy subjects using Affymetrix microarray technology. Our findings suggest that the relapsing-remitting pattern of MS is an ongoing process where inflammation is persistently active in the background of a changing magnitude of processes associated with TBX21-mediated immune suppression and activation of BDNF-related neuroprotection.
多发性硬化症(MS)的特征是大多数患者具有复发缓解病程。然而,复发的触发因素以及将复发转化为缓解的转化过程尚不清楚。为了评估在 MS 复发和缓解中起作用的关键分子途径,我们使用 Affymetrix 微阵列技术,对 123 名处于复发期(n=34)或缓解期(n=89)的 MS 患者以及 41 名匹配的健康对照者的外周血基因表达谱进行了分析。我们的研究结果表明,MS 的复发缓解模式是一个持续的过程,在与 TBX21 介导的免疫抑制和 BDNF 相关的神经保护激活相关的过程的变化幅度的背景下,炎症持续活跃。